Showing posts with label anal health. Show all posts
Showing posts with label anal health. Show all posts

Sunday, September 8, 2013

Sept 10 at #USCA2013 - Everything You Need to Know About #Anal Health

This Tuesday, September 10 at the United States Conference on AIDS in New Orleans join IRMA and friends from 4:30 p.m. to 6 p.m. for this fun workshop on anal health and rectal microbicide research and advocacy.

Session 5: Imperial 9, Level 4. See ya there - show your rectal pride!


-------------------

 *Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,200 advocates, scientists, policy makers and funders from all over the world.

*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro.

 *Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article's content.

 -------------------

Thursday, May 2, 2013

Facilitator's Guide for "The Rectal Revolution is Here" Video - English Version NOW Available

As many of our readers  know – in December IRMA, the Microbicide Trials Network, and Population Council launched the video “The Rectal Revolution is Here: An introduction to rectal microbicide clinical trials.” The 14-minute video includes researchers, advocates, and trial participants and discusses the need for rectal microbicides and the role of clinical trials in developing products that are safe and effective. It is available on YouTube in English, Spanish, and Thai and has been watched by several thousand viewers already.

The team has produced a facilitator’s guide to accompany the video, and the English version can be downloaded here.

The guide is meant to be used as a preparation tool for people leading community discussions, workshops, and/or recruitment sessions who will be showing the educational video. You will find simple, clear background information on rectal microbicide research and the clinical trial process as well as helpful hints on using the video.

We are still finalizing versions in Spanish and Thai – and will post them as soon as they are ready to go.

Many, many thanks to our partners at MTN and Population Council for their help and expertise with this guide, our Video Advisory Committee that provided invaluable feedback, our fabulous graphic designer from Toolbox, Inc., and to our intrepid Spanish and Thai translation teams!

If you would like an electronic copy of the video that you can keep on your computer or a flashdrive to be used for presentations, send a note to rectalmicro@gmail.com.

We hope you find this guide helpful!

-------------------

*Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,200 advocates, scientists, policy makers and funders from all over the world.

*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro.

*Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article's content.

-------------------

Thursday, July 19, 2012

Download Your Rectal Road Map to AIDS 2012

The AIDS 2012 Rectal Road Map put together by IRMA is a quick guide to rectal microbicide-related research and advocacy content + other selected sessions of interest at the International AIDS Conference in Washington, DC.

It's a big conference - you don't want to get lost, or miss any of these really great sessions!
IRMA's Rectal Road Map


Click "View on slideshare" - bottom left of the document - to download a copy of the Road Map.
-------------------

*Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,100 advocates, scientists, policy makers and funders from all over the world.

 *Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro.

*Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article's content.

Monday, July 9, 2012

IRMA is Turning the Tide Together - Please Join Us!


IRMA members are Turning the Tide Together at AIDS 2012 and beyond. Will you be like the IRMA members pictured above and join us?

To get involved in this AIDS 2012 awareness campaign, and to share what "Turning The Tide Together" means to you, download the template here and submit your photos to: photosAIDS2012@gmail.com.

Several other IRMA members have already participated. Check out their pics on Facebook here.

If you participate in this, please send copies of your photos to IRMA at rectalmicro@gmail.com so we can share them on the IRMA Facebook page and on our blog as well.
-------------------

*Join IRMA's robust, highly-active. moderated, global listserv addressing rectal microbicide research and advocacy as well as other interesting new HIV prevention technologies by contacting us at rectalmicro@gmail.com. Joining our listserv automatically makes you a member of IRMA - a network of more than 1,100 advocates, scientists, policy makers and funders from all over the world.

*Please look for us on Facebook: www.facebook.com/InternationalRectalMicrobicideAdvocates, and you can follow us on Twitter: @rectalmicro. *Also, please note that shared news items from other sources posted on this blog do not necessarily mean IRMA has taken any position on the article's content.

  -------------------

Thursday, April 19, 2012

Research on Douching Reveals Little Association to Sexually Transmitted Infections

via AIDSmap.com, by Gus Cairns

Neither rectal douching nor vaginal washing appear to be as significantly associated with sexually transmitted infections as had been feared, the International Microbicides Conference in Sydney heard yesterday.

In the case of women, vaginal washing and other vaginal health practices have been associated with bacterial vaginosis (BV), an imbalance in the types of bacteria that colonise the mucous surfaces of the vagina. BV can cause pelvic inflammatory disease and premature delivery in pregnant women and is associated with a higher risk of both acquiring and transmitting HIV.

The HPTN 035 trial of the candidate microbicide PRO2000 therefore included a survey of vaginal health practices, counselling against ones associated with a raised risk of BV, and assessing any link between these practices and BV. It found none, though a smaller study of women in Los Angeles did find an association not with douching and BV, but between the use of petroleum jelly as a lubricant and BV.

In the case of rectal douching in women and gay men, there is very little we currently know about the practice. However, findings over the last couple of years that the use of lubricants for anal sex, particularly water-based ones, is associated with higher rates of sexually transmitted infections have raised concerns that other practices that impact on the fragile rectal mucosa may also raise the risk of sexually transmitted infections (STIs) and HIV. International Rectal Microbicide Advocates (IRMA) have therefore conducted a survey of rectal douching practice. Interim results were presented yesterday and the survey is still ongoing.

Vaginal and rectal practices in women in HPTN 035 and in Los Angeles

In HPTN 035, vaginal hygiene practices were assessed at quarterly visits and the 3087 participants were counselled to try not to use the practices. They were divided into women who did not practise vaginal washing, ones who only used water and ones who used other products such as soap and water or commercial douches (Kasaro).

The proportion of women not practising any vaginal hygiene fell from 60% at baseline to 36.5% at last visit, and this was a steady fall over time, not just occurring immediately after the baseline visit.
Bacterial vaginosis (BV) was common at baseline and the proportion of women with it did not change over time – at any visit 36 to 38% of women had BV. There was no association between vaginal hygiene practices and BV.

Another study of women in Los Angeles (Brown) assessed vaginal hygiene and lubricant practices in an observational cohort of 141 women. The cohort was structured to reflect a mix of ethnicity and HIV serostatus: 26% had HIV and 40% were black, 34% white and 26% Latina. Their median age was 33 (range 18-65).

Read the Rest.


[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]

Tuesday, April 17, 2012

Sydney Microbicides 2012 Media Coverage : New Information on Lubricants and Anal Health

via Citizen News, by Bobby Ramakant

For how long will anal health and hygiene be neglected?


“It is high time that anal health [and hygiene] comes out of the closet” said Dr Ross Cranston, Assistant Professor, University of Pittsburgh, USA. Dr Cranston was referring to the multitude of anal health complications people practicing receptive anal intercourse are likely to be dealing with in their lives and very little quality care and products that exist to relieve them. Dr Cranston was speaking at the International Microbicides Conference (M2012) in Sydney, Australia. According to the UNAIDS, United Nations joint programme on HIV/AIDS, men-who-have-sex-with-men (MSM) are at a high risk of HIV around the world.
Many countries such as those in Africa who had earlier reported no significant HIV rates in people with same sex behaviour, have reported alarming HIV rates in recent past.

Although ‘anal’ and ‘rectal’ words are used as synonyms, but they aren’t same – and rather refer to different parts biologically. Anal canal is distinct from rectal canal with a unique set of diagnosis. Rectal canal is made up of columnar epithelial cells and anal canal is made up of stratified epithelial cells. Anal canal is also a high pressure environment with about 77 mmHg pressure when sphincters are resting and 180 mmHg pressure when sphincters constrict. In contrast, pressure in human vagina is 0 mmHg in resting phase.

Anal canal is very sensitive to hot, cold, wet, dry, light touch, pin prick, distension, pleasure or pain, however rectal canal is only sensitive to distension, pleasure or pain.
The incidence of adverse events in rectal microbicides studies is quite high with 11% symptoms and signs of anal adverse events in anal canal and 13% in rectal canal. These adverse events include prolapsing haemorrhoids (piles), anal fissure, anal fistula, anal abscess, anal warts, anal or rectal canal cancers, fungal infections, herpes simplex virus (HSV) infection, or sexually transmitted infections (STIs).

The need for right awareness in healthcare providers and their appropriate training is acute as often anal adverse events are misdiagnosed or ill-treated.

The awareness level in people (men and women) who reported to practice receptive anal intercourse was abysmally low. Zero per cent of such respondents had knowledge related to their anal cancer risk, and just half of them knew about HSV. Awareness certainly needs to be upped in people practicing receptive anal sex.

Read the Rest.

More safety data needed on lubricants used in anal sex


There is a growing realization that there is a significant issue of HIV acquisition through anal intercourse not only for men who have sex with men (MSM) who are clearly very visible HIV high risk group but increasingly for women who may be exposed to the virus through anal intercourse with their male partners. Also in recent studies, most people (men and women) who practice anal intercourse reported using some kind of a lubricant (such as gel, cream, or saliva among others).
So when the ongoing rectal microbicides research yields a safe and effective rectal microbicide towards later half of this decade, then rectal microbicide could be added to these lubricants as most people practicing anal intercourse are already comfortable with using lubricants, said Professor (Dr) Ian McGowan, Co-Chair of International Microbicides Conference (M2012) in Sydney, Australia; Professor, University of Pittsburgh School of Medicine, and co-principal investigator, Microbicide Trials Network (MTN).

Rectal microbicides are products that could take the form of gels or lubricants – being developed to reduce a person’s risk of HIV or other sexually transmitted infections (STIs) through anal receptive sex.

"What we have seen at this conference is that there is a growing evidence of MSM populations in African nations and HIV rates are alarmingly high in them" said Dr McGowan.
As per published data, not only MSM, there are number of women as well who reported to have anal sex. According to the data from a study in San Francisco, US, very high lubricant use was reported (89%) among those MSM who were practicing anal intercourse, said Dr Shauna Stahlman from Department of Epidemiology, University of California, Los Angeles (UCLA).

Read the Rest.


[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]

Thursday, April 12, 2012

The Risks Caused by Unprotected Anal Sex

via Australian Federation of AIDS Organisation, by Eric Glare

This article describes the biological role of anal mucus and its association with the gastrointestinal immune system, which harbours a persistent reservoir of HIV that potentially leads to infectious anal mucus. ERIC GLARE argues that all HIV prevention discussions should highlight the role anal mucus plays in HIV transmission.

Strategic positioning, where an HIV-negative man takes the insertive role inunprotected anal intercourse with an HIV-positive partner in order to reduce his risk of infection, has been associated with an intermediate incidence of HIV in cohorts of Sydney men who have sex with men (MSM).

Circumcision of the insertive partner and an undetectable blood plasma viral load in the receptive partner are two factors often cited as contributing to risk reduction in strategic positioning practices, despite there being a paucity of data on HIV transmission by anal intercourse in men who take the insertive role in male-to-male sex.

Men who practise strategic positioning are attempting to take perceived risks into account to form personalised boundaries around anal intercourse but, until recently, a comprehensive understanding of HIV transmission through insertive unprotected anal intercourse has not been widely canvassed in research literature.

A 2008 study of risk factors associated with HIV seroconversion in gay men in England identified that some men taking the insertive role in anal intercourse contracted HIV because they did not perceive that they were at risk of infection. GMFA, a gay men’s health charity based in the UK, responded with a campaign called Arse Facts that identified anal mucus as a body fluid containing HIV at potentially infectious levels.

Anal mucus is increasingly being mentioned in Australian campaigns as the infectious body fluid potentially infecting the insertive partner during unprotected anal intercourse. At times, the explanation of the role that anal mucus plays in transmitting HIV to the insertive partner has been relegated to in-depth discussions of topics such as risk reduction, but is frequently left out of more introductory information about HIV transmission (e.g. Whereversexhappens.com),and some campaigns discuss the risk of insertive anal intercourse without mentioning any body fluids involved.

Some campaigns warn that even if an HIV-positive person has an undetectable blood plasma viral load they might have higher viral load in anal mucus, particularly if they also have another STI. However, it should also be noted that a recent study, looking at men who have sex with men, found that plasma and rectal viral load were correlated, and that STI in the rectum did not increase the likelihood of detecting HIV in anal mucus, including those that had low or undetectable levels of HIV in their blood. This study suggests that a lower HIV viral load in blood plasma would also mean a lower viral load in anal mucus.

Read the Rest.



[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]

Thursday, April 5, 2012

Researchers Stress the Importance of Screening Women for Precancerous Anal Lesions

via AIDSmeds, by Tim Horn

Results from a study conducted in the Bronx, New York, serve as an important reminder to HIV care providers: Comprehensive screening for precancerous anal lesions isn’t of importance only to HIV-positive men who have sex with men (MSM). According to the Journal of Acquired Immune Deficiency Syndromes report by researchers at Albert Einstein College of Medicine in the Bronx, precancerous lesions are also common among women living with HIV—and testing for them using anal swabs alone may not be sufficient to rule out problems requiring biopsies.

Numerous studies have noted high rates of anal cancer among MSM. According to one study cited by June Hou, MD, and her colleagues at Albert Einstein, the incidence of anal cancer among MSM is 10 to 50 times that of the general population and comparable to cervical cancer incidence rates before the implementation of now-routine screening practices.

Among HIV-positive women, some studies put the incidence of anal cancer at seven to 28 times greater than the general population. Though the incidence of anal cancer has not been nearly as well studied in HIV-positive women compared with HIV-positive MSM, the confirmed higher rates of precancerous lesions—which can occur among women living with HIV, even if they’ve never engaged in anal sexual intercourse—remain a concern.

Yet there is no consensus between national and local groups on anal cancer screening among people living with HIV, either male or female. “Since 2007,” Hou and her colleague explain, “the New York State Department of Health (NYS DOH) has recommended annual anal cytology”—Dacron swabs analyzed by a laboratory—“in HIV-infected subjects with a history of [anal warts] or with abnormal cervical/vulvar histology, along with referral for high resolution anoscopy (HRA) in those with abnormal anal cytology or abnormal findings on anal exam. In contrast, the Department of Health and Human Services guidelines discourage screening and treatment programs for [anal intraepithelial neoplasia, or AIN] due to a lack of complete understanding of the relative harms and benefits of anal cytology screening.”

In turn, to better understand the incidence of precancerous anal lesions and the value of routine anal cytology, Hou and her colleagues conducted a study among women in the Bronx, which has one of the highest HIV prevalence rates in the country, representing 3 percent of the total U.S. HIV burden.

Read the Rest.


[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]

Wednesday, March 28, 2012

The Shamless Plug!


REGISTER FOR THIS CALL!

Raise your hand if you've ever felt uncomfortable talking about anal sex and anal health. Have you noticed that people sometimes tend to cringe from embarrassment when the word "rectal" is uttered? Or that they may laugh a little too much, or try to change the subject too quickly?

If you can identify with any of that - it means you're human - welcome to the club! Dealing with other people's reluctance to talk about anal sex, including our own reluctance, is common. But if we're going to be effective rectal microbicide advocates, let alone Rectal Rock Stars, we must get over our anal issues, and we must help others do the same. We must be absolutely shameless!

Enter Vanessa Marquez, a clinician at Fenway Community Health who has worked on several rectal microbicide trials, and uses a number of strategies to rectally disarm her patients and others to great effect. She will share her Shameless Plugs on this IRMA/AVAC teleconference - please join us for a really fun conversation.

You may follow along with Vanessa's slides on the ReadyTalk web interface, or you may download her presentation in advance from the IRMA website here: http://rectalmicrobicides.org/teleconf.php. They will be available no later than April 3.

The call is scheduled for 11am Eastern. Please convert the time for your location by following this link: http://www.timeanddate.com/worldclock/converter.html

The call will be recorded, and will be posted on the IRMA website after its completion here: http://rectalmicrobicides.org/teleconf.php.
 
 
 
[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]

Wednesday, February 15, 2012

Increased risk of anal cancer for all groups with HIV, not just MSM

via Aidsmap, by Michael Carter

Gay men are not the only group of HIV-positive patients who have an increased risk of anal cancer, according to North American research published in the online edition of Clinical Infectious Diseases. The researchers found that incidence of the cancer was also significantly higher in non-gay HIV-positive men as well as HIV-positive women when compared to individuals in the general population.

“We confirmed that HIV-infected MSM [men who have sex with men] experienced the greatest risk of anal cancer,” write the authors. “We also found that both HIV-infected other men and women had substantially higher rates than HIV-uninfected men and women, and that HIV-infected other men and women had similar rates.” They believe that their findings may have implications for anal cancer screening strategies.

Thanks to improvements in HIV treatment and care the prognosis of many HIV-positive patients is now near normal. However, HIV-positive patients appear more likely to develop certain malignancies, including anal cancer, compared to their HIV-negative peers.

Understanding the incidence of anal cancer in the different populations affected by HIV can help develop strategies to prevent the cancer.

Therefore investigators from the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) analysed findings from 13 US and Canadian studies. Their aims was to determine incidence of anal cancer in HIV-positive patients, who were divided into three categories – MSM, other men and women.

Rates of anal cancer in these HIV-positive patients were compared to those observed in HIV-negative men and women. Analyses were also conducted to see if there were temporal trends in anal cancer incidence, and if any specific risk factors for the malignancy in HIV-positive patients could be identified.

A total of 34,000 HIV-positive patients (55% MSM, 19% other men, 26% women) and 110,000 HIV-negative controls (90% men) were included in the study.

Data gathered between 1996 (the year effective HIV therapy first became available) and 2007 were examined by the investigators.

Incidence of anal cancer in MSM was 131 per 100,000 patient years. Among HIV-positive other men incidence of the malignancy was 46 per 100,000 years, and incidence in HIV-positive women was 30 per 100,000 person years. Incidence was therefore significantly higher in HIV-positive MSM compared to other men (p < 0.01). However, incidence rates for HIV-positive other men and women did not differ significantly.

Read the rest.


[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]

Tuesday, January 31, 2012

In Africa, Anal Sex Goes Hetero

by IRMA advocate Bisi Alimi (pictured in purple, with IRMA advocate Kadiri Audu at the recent Project ARM - Africa for Rectal Microbicides meeting held in Addis Ababa, Ethiopia.)

While I was in secondary school, I was always told that anal sex is something between two men. Many anti-gay activists have used this sexual practice as a means of attacking the gay movement. It is the core of the sodomy law in Africa and the buggery law in other part of the world.

However, recent studies have shown an increasing number of heterosexual people in Africa, mostly young people, are practising anal sex on a daily basis.
While the notion of sex in itself is a very difficult topic to tackle in the African setting, the mere fact that more and more straight couples in Africa are embarking on a rectal sexual journey for pleasure gives a call for concern – because most of this is unprotected by condoms. An act of unprotected anal intercourse is 10 to 20 times more likely to result in HIV transmission compared to an act of unprotected vaginal intercourse, due to the different biological characteristics of the rectum which make it much more susceptible to infection.

What do we know?

According to Morenike Ukpong, at IRMA’s recently concluded Project ARM - Africa for Rectal Microbicides strategic meeting in Addis Ababa held in advance of the 2011 ICASA, over 12% of young people in Nigeria are practising anal intercourse. In different studies done across Africa on the prevalence of anal sexual practice among heterosexuals, similar results were found.

An anonymous survey of 2,593 men and 1,818 women in Cape Town conducted by Kalichman et. al (2009) found out that 14% of men and 10% of women have engaged in anal sex in the last 3 months. Of this, only 67% of the men and only 50% of the women used condoms.

Rates among truck drivers in South Africa are also very high (Ramjee et. al 2002).

A recent study found that 42% of truck drivers are consistently engaging in anal intercourse with female sex workers. Not surprisingly, a high percentage of female sex workers reported ever having practiced anal intercourse. A recent study in Kenya reports 40% of female sex workers said they had practiced anal intercourse at least once (Schwandt et. all 2006).

This is not the end of revealing data. In Lane et. all (2006) , results showed that young people between the ages of 15-24 in South Africa engage in anal sexual behaviour. There is only a small difference between the sexes, with 5.5% of young males engaging in anal sexual behaviour and 5.3% of females.

More interesting is Matasha (1998). This study found that among primary school pupils in Tanzania, 9% had anal sex as their first sexual experience.

Taken together, these studies show that there is previously unknown frequent anal sexual behaviour among heterosexuals. However, the focus on anal sex and health for many years has been the limited to gay/MSM communities.

What are we getting wrong?

The focus of HIV prevention in Africa has always been primarily targeted at vaginal sex, and thereby prevention messages have by and large been to use condoms. We are now finding though that as straight people engage in anal sex, the likelihood of using condoms diminishes. For many, anal intercourse may be a form of virginity protection, or as a means to prevent pregnancy, and there is a common belief that anal intercourse carries no risk for HIV infection.

Dr. Karim of the famous CAPRISA 004 study argued that this sexual behaviour- when unprotected - could be driving a sizable amount of new HIV infections in Africa. In agreeing with him, I asked the question “is it time for us to broaden our scope of what HIV transmission looks like in Africa?”

If we still argue that HIV transmission in Africa is mainly heterosexual, are we assuming that the risk is only from unprotected vaginal intercourse? Or are we going to acknowledge the prevalence of unprotected anal intercourse among heterosexuals and address heterosexual transmission more broadly and honestly?

Not only we are overlooking the reality and the prevalence of this sexual behaviour among the general heterosexual population, but we are also missing the chance to reassess our prevention strategy and provide safer anal intercourse education irrespective of gender or sexual orientation.

Coupled with the myth that only MSM practice anal intercourse is a troublesome lack of knowledge about the ways to practice safer anal intercourse. One area in particular where accurate knowledge is lacking is the safe use of lubricants. In a presentation at the Project ARM strategic meeting by Brian Kanyemba from the Desmond Tutu HIV Foundation, he said that many people were using all kinds of things as a lubricant: olive oil, Vaseline, Vicks and even mayonnaise - none of which are condom-compatible.

Gay and straight couples need to know the facts about anal intercourse, and need condoms and condom-compatible lubricants to engage in this behaviour in a safer way.

Hope, and the future

Anal sex is a pleasurable sexual activity, and it can be safe when certain conditions are met. One of these conditions is using condoms with condom-compatible lubrication.

Another answer to safer anal sex is rectal microbicides - which would be a lube or a gel with anti-HIV properties.

The development of a safe and effective rectal microbicides could help everyone engaging in anal sex have a more pleasurable and safer sexual experience.

It is important to know however that it is not a replacement for condom use, but could be used as an additional option for protection. Ideally, one day we will have rectal microbicides that not only protect against HIV, but other STDs as well.

This sounds very promising, but while there is ongoing research, there is no microbicide product out there in the market yet. That does not mean we should not be hopeful.

As we drive towards zero HIV infection, it is also important we started looking at other prevention technologies that will be very easy for people to use without actually affecting their established sexual behaviours.

As IRMA’s rectal microbicides advocates sat down to work at the Project ARM meeting in Addis, one of the interesting things that came out was the need to intensify advocacy for rectal microbicides in many ways. This includes engaging with our community to let people know that anal sex is a human behaviour, both homosexual and heterosexual.

There is increasing need for information on anal sex and health and active involvement of NGOs in Africa. This campaign should also include NGOs working with African communities all over the world. We should also start the discussion with women, both young and old, that there is a need for more education around safer anal sex.

Rectal microbicides are looking like the part of future of HIV prevention, but for this dream to be achieved there is the need for everyone to be involved in the process – on both the research and advocacy fronts.

From civil societies to clinicians, doctors to government officials, international organizations and funders the world over, we need to all join the fight.

But while we await the rectal microbicides reality, we should not forget that when we talk anal sex, we should also scream… AND LUBE!!

As without the right use of the right lube, anal sex will not only be painful and unpleasant, but also puts the receptive partner in greater danger of receiving sexually transmitted infections- including HIV.

Anal sex is great, condom use is pleasure, but don’t forget AND LUBE.




[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]

Tuesday, January 17, 2012

Rectal Sexually Transmitted Infections and Lubricant Use

via Sexually Transmitted Diseases, by Pamina M. Gorbach, DrPH, Robert E. Weiss, PhD, Edward Fuchs, PA-C, Robin A. Jeffries, MS, Marjan Hezerah, PhD, Stephen Brown, MD, Alen Voskanian, MD, Edward Robbie, MPH, Peter Anton, MD, and Ross D. Cranston, MD

Background

Use of lubricant products is extremely common during receptive anal intercourse (RAI) yet has not been assessed as a risk for acquisition of sexually transmitted infections (STIs).

Methods

Between 2006 and 2008, a rectal health and behavior study was conducted in Baltimore and Los Angeles as part of the University of California, Los Angeles Microbicide Development Program (NIAID IPCP# #0606414). Participants completed questionnaires, and rectal swabs were tested for Neisseria gonorrhoeae and Chlamydia trachomatis with the Aptima Combo 2 assay, and blood was tested for syphilis (for RPR and TPHA with titer) and HIV. Of those reporting lubricant use and RAI, STI results were available for 380 participants. Univariate and multivariate regressions assessed associations of lubricant use in the past month during RAI with prevalent STIs.

Results

Consistent lubricant use during RAI in the past month was reported by 36% (137/380) of participants. Consistent past month lubricant users had a higher prevalence of STI than inconsistent users (9.5% vs. 2.9%; P 0.006). In a multivariable logistic regression model, testing positive for STI was associated with consistent use of lubricant during RAI in the past month (adjusted odds ratio: 2.98 95% confidence interval: 1.09, 8.15) after controlling for age, gender, study location, HIV status, and numbers of RAI partners in the past month.

Conclusions

Findings suggest some lubricant products may increase vulnerability to STIs. Because of wide use of lubricants and their potential as carrier vehicles for microbicides, further research is essential to clarify if lubricant use poses a public health risk.
 
Read the full study here.


[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]

Friday, December 16, 2011

Electrocautery ablation safe and effective to treat anal lesions

via aidsmap, by Michael Carter

A clinic-based intervention offers safe and effective treatment for high-grade pre-cancerous anal lesions, US investigators report in the online edition of the Journal of Acquired Immune Deficiency Syndromes.

Doctors at the Mount Sinai School of Medicine, New York, used a technique called electrocautery ablation to treat pre-cancerous anal lesions in 232 gay men, 132 of whom were HIV-positive.

Eighteen months after treatment, 83% of HIV-negative men and 69% of those with HIV were free of high-grade pre-cancerous anal lesions.

“Electrocautery ablation of high-grade anal squamous intraepithelial lesions is a safe and effective office-based procedure comparable to other available treatments,” comment the investigators.

Incidence of anal cancer has increased dramatically among gay men in recent years. HIV-positive gay men appear to be especially vulnerable to the disease, and its incidence is five-times higher in these patients compared to HIV-negative men.

Infection with high certain high-risk strains of human papillomavirus can cause cell changes in the anus, resulting in the formation of lesions. The severity of these changes is graded, and between 9% and 13% of high-grade lesions progress to anal cancer.

There are a number of treatments for these pre-cancerous lesions including infrared coagulation and topical creams such as imiquimod.

Another therapy is electrocautery ablation. The investigators described the procedure thus: “Using a gentle brushing technique the lesion was ablated [worn down] by moving [a] blade lightly across the surface like a paint-brush.” The therapy has a number of advantages and can be performed in clinics without the need for anaesthetic or sedation.

Investigators wished to assess the safety and effectiveness of this procedure. They therefore retrospectively analysed the notes of gay men who had the treatment between 2006 and 2010. The patients received an initial treatment and were then followed at intervals of three to six months and were provided with additional treatment if necessary.

Read the rest.


[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]

Tuesday, November 15, 2011

Getting to the Bottom of It

via Positively Aware, by Gary Bucher, MD, FAAFP

Getting to the bottom of it. Be proactive about anal health, by Doctor Gary Bucher, MD, FAAFR.I have witnessed and taken part in the many changes in HIV care over the past 25 years. At the beginning of the epidemic, silence and fear was the name of the game. It took HIV activists taking control of their health care destiny to force the medical community to treat the disease and the patient.

HIV is now a chronic treatable disease, but it has a whole new set of issues regarding conditions related to prematu cian should feel for any tender areas, thickened lesions, shallow indentations, firm masses, or other abnormalities. I also ask the patient if they have performed an anal self-exam by using their finger to feel around for any lumps or bumps inside their anus. This can help guide me when I perform the digital anorectal exam.

Anal Pap smears are performed in a similar fashion to cervical Pap smears, with the area being swabbed to collect cells, which are then examined under a microscope. They can detect abnormal cells (anal dysplasia), but the anal Pap smear may be less likely to correlate with the degree of anal dysplasia that can be seen on a biopsy of an anal lesion revealed by high resolution anoscopy (HRA). Because such specificity is lacking, and there haven’t been any evidence-based clinical trials to evaluate anal cancer screening methods in preventing anal cancer, many clinicians feel that anal Pap smears should not be done at this time. However, I agree with other experts in the field who have proposed yearly anal Pap smears for all HIV-positive individuals. If the anal Pap is normal, continued annual screening is suggested. Experts also recommend anal Pap smears every one to two years for other high-risk groups and if normal, continued screening every two or three years. If any abnormal cells are detected, HRA with biopsy is recommended. However, these guidelines may be limited by the need to train a greater number of clinicians in performing HRAs and biopsies. It is also important for these screening tests to be administered in a non-hospital setting, to maximize patient compliance with screening and follow-up.

High-risk HPV subtypes, especially 16 and 18, are associated with cervical, anal, penile, vulvar, vaginal, and oral cancers. Cervical cancer is an AIDS-defining malignancy and its incidence has been decreasing with aggressive screening and treatment of pre-cancerous lesions or higher grade cervical dysplasia. Cervical cancer affected 35-40 per 100,000 women in the general population prior to cervical cancer screening and treatment and has now decreased to about 8-10 per 100,000.

Read the rest.


[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]

Tuesday, October 18, 2011

IRMA Survey On Rect Douching and Enemas in 5 Languages - Please Participate!


IRMA and researchers at the University of California, Los Angeles (UCLA) School of Public Health are conducting a brief survey to help better understand the types of products people use rectally for anal sex including lubricants and enemas or douches.

Take the survey in English, Spanish, French, Chinese, or Russian
.

We're trying to gain a better understanding of rectal practices and behaviors that may affect the risk for sexually transmitted infections among people who practice anal intercourse and hope you - yes YOU - will fill out this brief anonymous survey (estimated time to complete: less than 15 minutes).

Please take the survey NOW and share this link widely!

[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]

Tuesday, August 23, 2011

HPV Vaccine Protects Women Against Anal Infection

via Medpage Today

A vaccine against human papillomavirus (HPV) protects women against two strains of the virus that causes anal cancer, researchers reported.

The vaccine (Cervarix) against HPV strains 16 and 18 offered "strong protection" against anal infection in a study whose main goal was to assess the efficacy of vaccination against cervical infection and pre-cancerous lesions, according to Aimée Kreimer, PhD, of the National Cancer Institute, and colleagues.

The protection was higher in women who did not have HPV infection when they were first given the vaccine, Kreimer and colleagues reported online in The Lancet Oncology.

Anal cancer is rare in women, with an annual incidence of about 1.5 per 100,000, but rates are rising, the researchers noted. The rate is higher than for men in general, but markedly lower than for men who have sex with men or those with HIV.

Most anal cancers are caused by HPV, with strains 16 and 18 responsible for up to 80% of cases, Kreimer and colleagues noted.

They tested the vaccine against anal infection in a subgroup of young adult women, ages 18 through 25, who enrolled in a community-based randomized trial of cervical vaccine efficacy in Costa Rica.

The 6,352 participants who came for the final blinded study visit, four years after their first of three vaccine shots, were asked to give an anal sample, and 4,210 did so, with a median follow-up of 48.1 months.

The researchers analyzed anal infection in the whole cohort and also in a subgroup of women who had been negative for HPV DNA and antibodies at the start of the trial. Patient characteristics in both groups were well-balanced, the researchers reported, including the proportions who got the vaccine and those who were in the control group, given hepatitis A vaccine.

Kreimer and colleagues found...

Read the rest.


[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]

Tuesday, June 14, 2011

KENYA: Rural MSM Too Afraid to Access HIV Health Services

Via PlusNews.

Discriminatory laws and a largely homophobic society mean that men who have sex with men (MSM) in Kenya generally find it difficult to access HIV-related information and health services, but rural MSM have an especially hard time.

When Kibet Kipsowen*, 30, a cattle keeper in Kenya’s Rift Valley Province, and his partner have sex, they use the oil-based jelly he applies when milking his cows; he’s never heard of a water-based lubricant, let alone used one. “Milking jelly is the only lubricant I have known for the last four years,” he told IRIN/PlusNews at his home in the village of Lanjuera.

Health practitioners discourage the use of oil-based lubricants for anal sex, as the oil degrades condoms, increasing the likelihood that they will break. Studies have found that most African MSM use oil-based lubricants, heightening their risk of contracting HIV.

According to a 2008 Modes of Transmission study conducted by UNAIDS and the government, MSM and prisoners account for 15.2 percent of new HIV infections in Kenya annually.

Kipsowen and his partner have been an item for a few years now, but dare not let anyone in their village know they are a couple. “Even people who have ‘normal’ sex do not speak about it - I can never reveal my sexuality or else I would risk being an outcast, or even be killed,” he said.

The only other person in the village who knows about his sexuality is Soita Wellapondi, a local nurse and social worker, and that’s only because Kipsowen visited her when he developed a sexually transmitted infection.

“At that time I had a lot of wounds in my anus; I felt so much pain that I thought I would die, yet I could not even confide to my own mother, brother or sister, and I could not visit a health centre,” he said.

He knew that by confiding in Wellapondi he risked his secret being revealed to the community, but he felt she was his only chance of accessing health care. “I bought him some antibiotics and pain killers; it was absolutely impossible to convince him to visit a health centre, even one far away where he is not known,” said Wellapondi.

Local health workers have very little experience and no training in dealing with MSM. A clinical officer at the Mogotio health centre near Lanjuera says he has only ever had one MSM client.

Even people who have 'normal' sex do not speak about it - I can never reveal my sexuality or else I would risk being an outcast or even be killed“He came here for treatment of injuries resulting from anal sex, and was advised to come for further treatment but he never came back,” said the clinical officer, who declined to be named.


Read the rest here.

[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]

Friday, May 20, 2011

Vietnam: Gay rights group tackles insensitive medical care

Doctors believed, for example, that becoming a homosexual was a fashion statement. They teased gay patients, and criticised anal sex despite training on gay issues, the survey revealed.
via VietNamNet

Nguyen Thanh Trung (not his real name), a gay man who lives in Ha Noi, was very upset by the way doctors discriminated against him when he was undergoing an anal health test in one of the city's many health clinics.

"The doctor told me to my face that having sex with men is not a natural act and asked me why I did it," Trung recalled.

"I was so upset that I left the clinic and will never return," he said.


Read the rest.




[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]

Sunday, May 1, 2011

Description of a Pilot Anal Pap Smear Screening Program Among Individuals Attending a Veteran's Affairs HIV Clinic

via AIDS Patient Care and STDs

Isabella Rosa-Cunha, Vincent A. DeGennaro, Rene Hartmann, Clara Milikowski, Andres Irizarry, Brenda Heitman, Orlando Gómez-Marín, Gordon M. Dickinson. AIDS Patient Care and STDs. April 2011, 25(4): 213-219. doi:10.1089/apc.2010.0233.

Abstract

Despite the higher risk of anal cancer among HIV-infected individuals currently there are no national or international guidelines for anal dysplasia screening. We assessed acceptance and feasibility of screening for anal intraepithelial neoplasia (AIN), the rate of abnormalities, and relationship between the presence of AIN and a history of receptive anal intercourse. Eighty-two percent of HIV-patients approached during routine clinic visit agreed to participate in the study with anal Pap smear collection; 53% had abnormal cytology results and among those undergoing high-resolution anoscopy with biopsy, 55% had high-grade AIN, including 2 cases of carcinoma in situ. Anal cytology was well accepted and it was feasible to be incorporated into HIV primary care practice. Abnormal cytology was not significantly associated with history of anal intercourse (p = 0.767). The high rate of abnormal results reinforces the need for further evaluation of the role of systematic anal Pap smear screening for HIV patients.

Read the whole paper.

[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]

Tuesday, March 1, 2011

Pittsburgh's Dynamic Rectal Duo

IRMA Scientific Vice Chair Ian McGowan and his research/life partner, Ross Cranston (also a member of the IRMA Steering Committee) are featured in CUE Pittsburgh this month. They talk about our favorite topic - rectal microbicides - and a trial taking place right in Pittsburgh that gay men can get involved in.

The article, below, starts on Page 17. Use the arrows on both sides of the magazine to "flip" pages forward and back.






[If an item is not written by an IRMA member, it should not be construed that IRMA has taken a position on the article's content, whether in support or in opposition.]
Related Posts Plugin for WordPress, Blogger...